5 Key Takeaways | AI and Your Patent Management, Strategy & Portfolio
(Podcast) The Briefing: The Future of TV? A 2025 Digital Media Trends Analysis
The Privacy Insider Podcast Episode 13: Preserving Privacy and Social Connection with Christine Rosen of the American Enterprise Institute
Great Women in Compliance: Creating Space to Speak Up: The Story Behind Psst.org
JONES DAY TALKS®: Women in IP – AI and Copyright Law Need-to-Knows
No Password Required: SVP at SpyCloud Labs, Former Army Investigator, and Current Breakfast Champion
Compliance into the Weeds: The Role of Compliance Going Forward
A Less is More Strategy for Data Risk Mitigation
Third-Party Risk The competitive world of banking struggles to keep up with technological advances, particularly in a regulatory environment.
Investment Opportunities in Italy's Tech Market
The AI Shakeup: New Tech Innovations and the Future of Corporate Law
Regulatory Ramblings: Episode 44 - The Dangers of Non-Technically Trained Lawyers Advising on Technological Matters with Ronald Yu and Donald Day
[Webinar] AI and Data Privacy: Minimizing Risk and Maximizing Opportunity
Tips and Trends in Thought-Leadership Marketing
Guidepost in Motion EP27: Privacy Matters Part 2: “TMI”-The Privacy Dilemma of Social Media
Hospice Innovators: A Conversation with Jaysen Roa, President and CEO of Avow Hospice
Innovation in Compliance - Lessons About Leadership and Security with Paul Clayson
RPA As A Digital Transformation Catalyst
JONES DAY PRESENTS® Digital Health and Clinical Research: Understanding Regulatory Regimes
31 Days to a More Effective Compliance Program - Originating a Compliance Ecosystem
In this note, we will discuss the latest decisions on the merits from the Dutch patent court on the matter of plausibility and inventive step. These were handed down in two cases (BMS v Sandoz and BMS v Teva) on 30 October...more
On Nov. 7, 2023, the Federal Trade Commission (FTC) announced it is disputing the listing of more than 100 patents in the Food and Drug Administration’s (FDA) “Approved Drug Products with Therapeutic Equivalence Evaluations,”...more
Last week, the Federal Circuit held that obviousness-type double patenting trumps patent term adjustment, opening the door for invalidity attacks that to date had been questionable. In re Cellect was an appeal from a...more